Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland

Virchows Archiv

Volumn 460, Issue 3, 2012, Pages 319-325

  Barresi, Valeria ^a   Vitarelli, Enrica ^a   Bonetti, Luca Reggiani ^b   Tuccari, Giovanni ^a   Barresi, Gaetano ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Biotin; Differential diagnosis; NGAL; Thyroid

Indexed keywords

BIOTIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; STREPTAVIDIN; ACUTE PHASE PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROID DISEASE; THYROID GLAND; BIOSYNTHESIS; CARCINOMA; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ACUTE-PHASE PROTEINS; ADULT; AGED; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOCALINS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; SENSITIVITY AND SPECIFICITY; THYROID DISEASES; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860326036     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1208-0     Document Type: Article

References (34)

1. Yang J, Goetz D, Li JY et al (2002) An iron delivery pathway mediated by a lipocalin. Mol Cell 10:1045-1056 (Pubitemid 35453824)
2. Goetz DH, Willie ST, Arme RS et al (2000) Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry 39:1935-1941 (Pubitemid 30124000)
3. Bauer M, Eickhoff JC, Gould MN et al (2008) Neutrophil gelatinase- associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat 108:389-397 (Pubitemid 351431077)
4. Iannetti A, Pacifico F, Acquaviva R et al (2008) The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci U S A 105:14058-14063
5. Barresi V, Ieni A, Bolignano D et al (2010) Neutrophil gelatinaseassociated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Oncol Rep 24:305-310
6. Barresi V, Lucianò R, Vitarelli E et al (2010) Neutrophil gelatinaseassociated lipocalin immunoexpression in colorectal carcinoma: a stage-specific prognostic factor? Oncol Lett 1:1089-1096
7. Barresi V, Tuccari G, Barresi G (2010) NGAL immunohistochemical expression in brain primary and metastatic tumors. Clin Neuropathol 29:317-322
8. Barresi V, Di Gregorio C, Regiani-Bonetti L et al (2011) Neutrophil gelatinase-associated lipocalin (NGAL): a new prognostic marker in stage I colorectal carcinoma? Hum Pathol 42:1720-1726
9. Bratt T (2000) Lipocalins and cancer. Biochim Biophys Acta 1482:318-326
10. Devireddy LR, Gazin C, Zhu X et al (2005) A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 23:1293-1305 (Pubitemid 41821786)
11. Le NT, Richardson DR (2002) The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta 1603:3146
12. Yan L, Borregaard N, Kjeldsen L et al (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276:37258-37265
13. Hu L, HittelmanW, Lu T et al (2009) NGAL decreases E-cadherinmediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest 89:531-548
14. Barresi V, Ieni A, Tuccari G et al (2012) Neutrophil gelatinaseassociated lipocalin (NGAL) immunohistochemical expression in follicular cell-derived thyroid tumors: a novel diagnostic tool? Histol Histopathol (in press)
15. Bussolati G, Gugliotta P, Volante M et al (1997) Retrieved endogenous biotin: a novel marker and a potential pitfall in diagnostic immunohistochemistry. Histopathology 31:400-407 (Pubitemid 27505355)
16. Nikiel B, Chekan M, Jarzab M et al (2009) Endogenous avidin biotin activity (EABA) in thyroid pathology: immunohistochemical study. Thyroid Res 2:5
17. De Lellis RA, Lloyd RV, Heitz PU et al (2004) Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon
18. Livolsi VA, Baloch ZW (2011) Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain. Endocr Pathol 22:184-189
19. Hirokawa M, Carney JA, Goellner JR et al (2002) Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 26:1508-1514 (Pubitemid 35239428)
20. Elsheikh TM, Asa SL, Chan JK et al (2008) Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol 130:736-744
21. Sahoo S, Hoda SA, Rosai J et al (2001) Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 116:696-702 (Pubitemid 34453210)
22. Herrmann ME, LiVolsi VA, Pasha TL et al (2002) Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 126:710-713 (Pubitemid 34602574)
23. Erickson LA, Lloyd RV (2004) Practical markers used in the diagnosis of endocrine tumors. Adv Anat Pathol 11:175-189
24. Prasad ML, Pellegata NS, Huang Y et al (2005) Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 18:48-57 (Pubitemid 40128094)
25. Cho Mar K, Eimoto T, Tateyama H et al (2006) Expression of matrix metalloproteinases in benign and malignant follicular thyroid lesions. Histopathology 48:286-294
26. Cho Mar K, Eimoto T, Nagaya S et al (2006) Cell proliferation marker MCM2, but not Ki67, is helpful for distinguishing between minimally invasive follicular carcinoma and follicular adenoma of the thyroid. Histopathology 48:801-807 (Pubitemid 43800939)
27. Barroeta JE, Baloch ZW, Lal P et al (2006) Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr Pathol 17:225-234 (Pubitemid 46279670)
28. El Demellawy D, Nasr A, Alowami S (2008) Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol 3:5
29. Buergy D, Weber T, Maurer GD et al (2009) Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 125:894-901
30. Saleh HA, Jin B, Barnwell J et al (2010) Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 26:5-9
31. Fernandez CA, Yan L, Louis G et al (2005) The matrix metalloproteinase- 9/neutrophil gelatinase associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11:5390-5395 (Pubitemid 41060812)
32. Lee S, Jilani SM, Nikolova GVet al (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681-691 (Pubitemid 41002860)
33. Kim SH, Jung KC, Shin YK et al (2002) The enhanced reactivity of endogenous biotin-like molecules by antigen retrieval procedures and signal amplification with tyramine. Histochem J 34:97-103 (Pubitemid 35398659)
34. Rosai J, Kuhn E, Carcangiu ML (2006) Pitfalls in thyroid tumour pathology. Histopathology 49:107-120 (Pubitemid 44079694)